• MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

American Academy of Neurology Annual Meeting

The Need to Find Valuable Parkinson Disease Biomarkers: Mark Lew, MD

May 23, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the early reactions behind reflex tears as a potential biomarker for Parkinson disease. [WATCH TIME: 2 minutes]

Progress in Neurogenerative Disease Drug Development: Gregory A. Rippon, MD, MS

May 19, 2022

The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]

Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc

May 19, 2022

The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against recommending approval for AMX0035 in ALS. [WATCH TIME: 3 minutes]

NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease

May 18, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.

Validating Tears as a Biomarker in Atypical Presentations of Parkinson Disease: Mark Lew, MD

May 11, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the efforts needed to validate tears as a biomarker in patients who don’t present with typical Parkinson disease. [WATCH TIME: 4 minutes]

The Future of Tears as a Biomarker for Neurodegenerative Disorders: Mark Lew, MD

May 09, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps in how we can expand on tears as a valuable biomarker for neurodegenerative diseases. [WATCH TIME: 4 minutes]

The Motivations for Using Tears to Confirm Parkinson Disease Diagnosis: Mark Lew, MD

May 06, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine commented on the potential of reflex tears as a critical biomarker of Parkinson disease. [WATCH TIME: 6 minutes]

Cognitive Outcome Measures May Help Predict Disease-Modifying Therapy Response in MS

May 03, 2022

Using this new methodology, 78% of patients with progressive multiple sclerosis demonstrated large treatment benefits with the siponimod (Mayzent; Novartis) on at least 1 of 4 clinical outcomes.

Predicting Patient Response to MS Treatment Using Cognitive Outcome Measures: Ludwig Kappos, MD, FEAN, FAAN

May 02, 2022

The professor of neurology at the University of Basel provided insight on a new methodology that allows depiction of patient profiles from baseline characteristics and their associations with individual outcomes. [WATCH NOW: 5 minutes]

Regenerative Medicine for Neurologic Injury and the Potential of SB623

April 29, 2022

Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.